Skip to main content
Erschienen in: Drugs & Aging 1/2009

01.12.2009 | Review Article

Variability in the Prescription of Cardiovascular Medications in Older Patients

Correlates and Potential Explanations

verfasst von: Dr Cinzia Maraldi, Fabrizia Lattanzio, Graziano Onder, Massimo Gallerani, Silvia Bustacchini, Giuseppe De Tommaso, Stefano Volpato

Erschienen in: Drugs & Aging | Sonderheft 1/2009

Einloggen, um Zugang zu erhalten

Abstract

In western countries approximately a quarter of the population is 65 years and older. People in this age group often have several coexisting medical problems and take multiple drugs, and older people receive the greatest proportion of dispensed prescriptions. The prevalence of cardiovascular diseases, the leading cause of death and a major cause of physical and cognitive disability, increases steeply with increasing age. Drugs for the prevention and treatment of cardiovascular conditions account for a large proportion of medication prescription in older persons. Despite a number of published guidelines and expert recommendations supporting a standardized use of many cardiovascular agents, there is growing evidence of a tremendous variability in cardiovascular drug prescriptions according to demographics, health characteristics, and setting of care. In particular, evidence shows an inverse relationship between treatment propensity and age. To date, there is little evidence of benefit of most pharmacotherapy in frail, older subjects or elderly individuals with multiple comorbidities and polypharmacotherapy. However, effective treatment should not be denied solely on the basis of age. A major challenge in geriatric practice is to ensure safe and effective pharmacological treatments, avoiding the risk of polypharmacy and inappropriate drug prescription.
Literatur
1.
Zurück zum Zitat Day JC. National population projections. US Census Bureau 2001 Day JC. National population projections. US Census Bureau 2001
2.
Zurück zum Zitat Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics — 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008; 117(4): e25–146PubMed Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics — 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008; 117(4): e25–146PubMed
3.
Zurück zum Zitat Sans S, Kesteloot H, Kromhout D. The burden of cardiovascular diseases mortality in Europe. Task Force of the European Society of Cardiology on Cardiovascular Mortality and Morbidity Statistics in Europe. Eur Heart J 1997; 18(12): 1231–48 Sans S, Kesteloot H, Kromhout D. The burden of cardiovascular diseases mortality in Europe. Task Force of the European Society of Cardiology on Cardiovascular Mortality and Morbidity Statistics in Europe. Eur Heart J 1997; 18(12): 1231–48
4.
Zurück zum Zitat Denke MA, Grundy SM. Hypercholesterolemia in elderly persons: resolving the treatment dilemma. Ann Intern Med 1990; 112(10): 780–92PubMed Denke MA, Grundy SM. Hypercholesterolemia in elderly persons: resolving the treatment dilemma. Ann Intern Med 1990; 112(10): 780–92PubMed
5.
Zurück zum Zitat Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997; 349(9063): 1436–42PubMed Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997; 349(9063): 1436–42PubMed
6.
Zurück zum Zitat Lauria G, Gentile M, Fassetta G, et al. Incidence and prognosis of stroke in the Belluno province, Italy. First-year results of a community-based study. Stroke 1995; 26(10): 1787–93PubMed Lauria G, Gentile M, Fassetta G, et al. Incidence and prognosis of stroke in the Belluno province, Italy. First-year results of a community-based study. Stroke 1995; 26(10): 1787–93PubMed
7.
Zurück zum Zitat Feigin VL, Lawes CM, Bennett DA, et al. Stroke epidemiology: a review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century. Lancet Neurol 2003; 2(1): 43–53PubMed Feigin VL, Lawes CM, Bennett DA, et al. Stroke epidemiology: a review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century. Lancet Neurol 2003; 2(1): 43–53PubMed
8.
Zurück zum Zitat Whitworth JA, World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003 Nov; 21(11): 1983–92PubMed Whitworth JA, World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003 Nov; 21(11): 1983–92PubMed
9.
Zurück zum Zitat Popovic JR, Kozak LJ. National hospital discharge survey: annual summary. Vital Health Stat 2000 Sep; 13(148): 1–194 Popovic JR, Kozak LJ. National hospital discharge survey: annual summary. Vital Health Stat 2000 Sep; 13(148): 1–194
10.
Zurück zum Zitat Singer DE, Albers GW, Dalen JE, et al. American College of Chest Physicians. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008 Jun; 133 (6 Suppl.): 546–92S Singer DE, Albers GW, Dalen JE, et al. American College of Chest Physicians. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008 Jun; 133 (6 Suppl.): 546–92S
11.
Zurück zum Zitat Chobanian AV, Bakris GL, Black HR, et al. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003 Dec; 42(6): 1206–52. Epub 2003 Dec 1PubMed Chobanian AV, Bakris GL, Black HR, et al. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003 Dec; 42(6): 1206–52. Epub 2003 Dec 1PubMed
12.
Zurück zum Zitat National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002 Dec 17; 106(25): 3143–421 National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002 Dec 17; 106(25): 3143–421
13.
Zurück zum Zitat Smith Jr SC, Allen J, Blair SN, et al. AHA/ACC; National Heart, Lung, and Blood Institute. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006 May 16; 113(19): 2363–72. Erratum in: Circulation 2006 Jun 6; 113 (22): e847PubMed Smith Jr SC, Allen J, Blair SN, et al. AHA/ACC; National Heart, Lung, and Blood Institute. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006 May 16; 113(19): 2363–72. Erratum in: Circulation 2006 Jun 6; 113 (22): e847PubMed
14.
Zurück zum Zitat Sacco RL, Adams R, Albers G, et al., American Heart Association; American Stroke Association Council on Stroke; Council on Cardiovascular Radiology and Intervention; American Academy of Neurology. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: cosponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke 2006 Feb; 37(2): 577–617PubMed Sacco RL, Adams R, Albers G, et al., American Heart Association; American Stroke Association Council on Stroke; Council on Cardiovascular Radiology and Intervention; American Academy of Neurology. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: cosponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke 2006 Feb; 37(2): 577–617PubMed
15.
Zurück zum Zitat Milton JC, Hill-Smith I, Jackson SH. Prescribing for older people. BMJ 2008; 336(7644): 606–9PubMed Milton JC, Hill-Smith I, Jackson SH. Prescribing for older people. BMJ 2008; 336(7644): 606–9PubMed
16.
Zurück zum Zitat Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002 Jan 12; 324(7329): 71–86. Erratum in: BMJ 2002; 324 (7330): 141 Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002 Jan 12; 324(7329): 71–86. Erratum in: BMJ 2002; 324 (7330): 141
17.
Zurück zum Zitat Whitford DL, Southern AJ. Audit of secondary prophylaxis after myocardial infarction. BMJ 1994 Nov 12; 309(6964): 1268–9PubMed Whitford DL, Southern AJ. Audit of secondary prophylaxis after myocardial infarction. BMJ 1994 Nov 12; 309(6964): 1268–9PubMed
18.
Zurück zum Zitat Volpato S, Maraldi C, Ble` A, et al. Prescription of antithrombotic therapy in older patients hospitalized for transient ischemic attack and ischemic stroke: the GIFA study. Stroke 2004; 35(4): 913–17PubMed Volpato S, Maraldi C, Ble` A, et al. Prescription of antithrombotic therapy in older patients hospitalized for transient ischemic attack and ischemic stroke: the GIFA study. Stroke 2004; 35(4): 913–17PubMed
19.
Zurück zum Zitat Brass LM, Krumholz HM, Scinto JM, et al. Warfarin use among patients with atrial fibrillation. Stroke 1997; 28(12): 2382–9PubMed Brass LM, Krumholz HM, Scinto JM, et al. Warfarin use among patients with atrial fibrillation. Stroke 1997; 28(12): 2382–9PubMed
20.
Zurück zum Zitat Hillen T, Dundas R, Lawrence E, et al. Antithrombotic and antihypertensive management 3 months after ischemic stroke: a prospective study in an inner city population. Stroke 2000 Feb; 31(2): 469–75PubMed Hillen T, Dundas R, Lawrence E, et al. Antithrombotic and antihypertensive management 3 months after ischemic stroke: a prospective study in an inner city population. Stroke 2000 Feb; 31(2): 469–75PubMed
21.
Zurück zum Zitat Landi F, Cesari M, Onder G, et al., SILVERNET-HC Study Group. Antithrombotic drugs in secondary stroke prevention among a community dwelling older population. J Neurol Neurosurg Psychiatry 2003; 74(8): 1100–4PubMed Landi F, Cesari M, Onder G, et al., SILVERNET-HC Study Group. Antithrombotic drugs in secondary stroke prevention among a community dwelling older population. J Neurol Neurosurg Psychiatry 2003; 74(8): 1100–4PubMed
22.
Zurück zum Zitat Khunti K, Sorrie R, Jennings S, et al. Improving aspirin prophylaxis after myocardial infarction in primary care: collaboration in multipractice audit between primary care audit group and health authority. BMJ 1999; 319(7205): 297PubMed Khunti K, Sorrie R, Jennings S, et al. Improving aspirin prophylaxis after myocardial infarction in primary care: collaboration in multipractice audit between primary care audit group and health authority. BMJ 1999; 319(7205): 297PubMed
23.
Zurück zum Zitat Feinberg WM, Blackshear JL, Laupacis A, et al. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med 1995 Mar 13; 155(5): 469–73PubMed Feinberg WM, Blackshear JL, Laupacis A, et al. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med 1995 Mar 13; 155(5): 469–73PubMed
24.
Zurück zum Zitat Broderick JP, Phillips SJ, O’Fallon WM, et al. Relationship of cardiac disease to stroke occurrence, recurrence, and mortality. Stroke 1992; 23(9): 1250–6PubMed Broderick JP, Phillips SJ, O’Fallon WM, et al. Relationship of cardiac disease to stroke occurrence, recurrence, and mortality. Stroke 1992; 23(9): 1250–6PubMed
25.
Zurück zum Zitat Hart RG, Halperin JL. Atrial fibrillation and thromboembolism: a decade of progress in stroke prevention. Ann Intern Med 1999 Nov 2; 131(9): 688–95PubMed Hart RG, Halperin JL. Atrial fibrillation and thromboembolism: a decade of progress in stroke prevention. Ann Intern Med 1999 Nov 2; 131(9): 688–95PubMed
26.
Zurück zum Zitat Albers GW, Sherman DG, Gress DR, et al. Stroke prevention in nonvalvular atrial fibrillation: a review of prospective randomized trials. Ann Neurol 1991; 30(4): 511–18PubMed Albers GW, Sherman DG, Gress DR, et al. Stroke prevention in nonvalvular atrial fibrillation: a review of prospective randomized trials. Ann Neurol 1991; 30(4): 511–18PubMed
27.
Zurück zum Zitat Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991 Aug; 22(8): 983–8PubMed Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991 Aug; 22(8): 983–8PubMed
28.
Zurück zum Zitat Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. Arch Intern Med 1987; 147(9): 1561–4PubMed Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. Arch Intern Med 1987; 147(9): 1561–4PubMed
29.
Zurück zum Zitat Jørgensen HS, Nakayama H, Reith J, et al. Acute stroke with atrial fibrillation. The Copenhagen Stroke Study. Stroke 1996 Oct; 27(10): 1765–9PubMed Jørgensen HS, Nakayama H, Reith J, et al. Acute stroke with atrial fibrillation. The Copenhagen Stroke Study. Stroke 1996 Oct; 27(10): 1765–9PubMed
30.
Zurück zum Zitat Akhtar W, Reeves WC, Movahed A. Indications for anticoagulation in atrial fibrillation. Am Fam Physician 1998; 58(1): 130–6. Review. Erratum in: Am Fam Physician 1999; 59 (5): 1122PubMed Akhtar W, Reeves WC, Movahed A. Indications for anticoagulation in atrial fibrillation. Am Fam Physician 1998; 58(1): 130–6. Review. Erratum in: Am Fam Physician 1999; 59 (5): 1122PubMed
31.
Zurück zum Zitat Connolly SJ, Laupacis A, Gent M, et al. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol 1991; 18(2): 349–55PubMed Connolly SJ, Laupacis A, Gent M, et al. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol 1991; 18(2): 349–55PubMed
32.
Zurück zum Zitat EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993 Nov 20; 342(8882): 1255–62 EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993 Nov 20; 342(8882): 1255–62
33.
Zurück zum Zitat Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med 1992; 327(20): 1406–12. Erratum in: N Engl J Med 1993; 328 (2): 148PubMed Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med 1992; 327(20): 1406–12. Erratum in: N Engl J Med 1993; 328 (2): 148PubMed
34.
Zurück zum Zitat Petersen P, Boysen G, Godtfredsen J, et al. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1989; 1(8631): 175–9PubMed Petersen P, Boysen G, Godtfredsen J, et al. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1989; 1(8631): 175–9PubMed
35.
Zurück zum Zitat Cairns JA. Stroke prevention in atrial fibrillation trial. Circulation 1991; 84(2): 933–5PubMed Cairns JA. Stroke prevention in atrial fibrillation trial. Circulation 1991; 84(2): 933–5PubMed
36.
Zurück zum Zitat The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with non-rheumatic atrial fibrillation. N Engl J Med 1990; 323(22): 1505–11 The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with non-rheumatic atrial fibrillation. N Engl J Med 1990; 323(22): 1505–11
37.
Zurück zum Zitat Thomson R, Parkin D, Eccles M, et al. Decision analysis and guidelines for anticoagulant therapy to prevent stroke in patients with atrial fibrillation. Lancet 2000; 355(9208): 956–62. Erratum in: Lancet 2000; 355 (9213): 1466PubMed Thomson R, Parkin D, Eccles M, et al. Decision analysis and guidelines for anticoagulant therapy to prevent stroke in patients with atrial fibrillation. Lancet 2000; 355(9208): 956–62. Erratum in: Lancet 2000; 355 (9213): 1466PubMed
38.
Zurück zum Zitat The Clinical Quality Improvement Network (CQIN) Investigators. Thromboembolic prophylaxis in 3575 hospitalized patients with atrial fibrillation. Can J Cardiol 1998; 14(5): 695–702 The Clinical Quality Improvement Network (CQIN) Investigators. Thromboembolic prophylaxis in 3575 hospitalized patients with atrial fibrillation. Can J Cardiol 1998; 14(5): 695–702
39.
Zurück zum Zitat Nieuwlaat R, Capucci A, Lip GY, et al. Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2006; 27(24): 3018–26PubMed Nieuwlaat R, Capucci A, Lip GY, et al. Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2006; 27(24): 3018–26PubMed
40.
Zurück zum Zitat Mohr JP, Albers GW, Amarenco P, et al. American Heart Association Prevention Conference. IV. Prevention and Rehabilitation of Stroke. Etiology of stroke. Stroke 1997; 28(7): 1501–6PubMed Mohr JP, Albers GW, Amarenco P, et al. American Heart Association Prevention Conference. IV. Prevention and Rehabilitation of Stroke. Etiology of stroke. Stroke 1997; 28(7): 1501–6PubMed
41.
Zurück zum Zitat Antani MR, Beyth RJ, Covinsky KE, et al. Failure to prescribe warfarin to patients with nonrheumatic atrial fibrillation. J Gen Intern Med 1996; 11(12): 713–20PubMed Antani MR, Beyth RJ, Covinsky KE, et al. Failure to prescribe warfarin to patients with nonrheumatic atrial fibrillation. J Gen Intern Med 1996; 11(12): 713–20PubMed
42.
Zurück zum Zitat Munschauer FE, Priore RL, Hens M, et al. Thromboembolism prophylaxis in chronic atrial fibrillation. Practice patterns in community and tertiary-care hospitals. Stroke 1997; 28(1): 72–6PubMed Munschauer FE, Priore RL, Hens M, et al. Thromboembolism prophylaxis in chronic atrial fibrillation. Practice patterns in community and tertiary-care hospitals. Stroke 1997; 28(1): 72–6PubMed
43.
Zurück zum Zitat McCormick D, Gurwitz JH, Goldberg RJ, et al. Prevalence and quality of warfarin use for patients with atrial fibrillation in the long-term care setting. Arch Intern Med 2001; 161(20): 2458–63PubMed McCormick D, Gurwitz JH, Goldberg RJ, et al. Prevalence and quality of warfarin use for patients with atrial fibrillation in the long-term care setting. Arch Intern Med 2001; 161(20): 2458–63PubMed
44.
Zurück zum Zitat Ansell J, Hollowell J, Pengo V, et al. Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the international study of anticoagulation management (ISAM). J Thromb Thrombolysis 2007; 23(2): 83–91PubMed Ansell J, Hollowell J, Pengo V, et al. Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the international study of anticoagulation management (ISAM). J Thromb Thrombolysis 2007; 23(2): 83–91PubMed
45.
Zurück zum Zitat Wilson PW, Anderson KM, Harris T, et al. Determinants of change in total cholesterol and HDL-C with age: the Framingham Study. J Gerontol 1994; 49(6): M252–7PubMed Wilson PW, Anderson KM, Harris T, et al. Determinants of change in total cholesterol and HDL-C with age: the Framingham Study. J Gerontol 1994; 49(6): M252–7PubMed
46.
Zurück zum Zitat Wilson PW, Kannel WB. Obesity, diabetes, and risk of cardiovascular disease in the elderly. Am J Geriatr Cardiol 2002; 11(2): 119–23; 125PubMed Wilson PW, Kannel WB. Obesity, diabetes, and risk of cardiovascular disease in the elderly. Am J Geriatr Cardiol 2002; 11(2): 119–23; 125PubMed
47.
Zurück zum Zitat Krumholz HM, Seeman TE, Merrill SS, et al. Lack of association between cholesterol and coronary heart disease mortality and morbidity and all-cause mortality in persons older than 70 years. JAMA 1994; 272(17): 1335–40PubMed Krumholz HM, Seeman TE, Merrill SS, et al. Lack of association between cholesterol and coronary heart disease mortality and morbidity and all-cause mortality in persons older than 70 years. JAMA 1994; 272(17): 1335–40PubMed
48.
Zurück zum Zitat Chyou PH, Eaker ED. Serum cholesterol concentrations and all-cause mortality in older people. Age Ageing 2000; 29(1): 69–74PubMed Chyou PH, Eaker ED. Serum cholesterol concentrations and all-cause mortality in older people. Age Ageing 2000; 29(1): 69–74PubMed
49.
Zurück zum Zitat Simons LA, Simons J, Friedlander Y, et al. Cholesterol and other lipids predict coronary heart disease and ischaemic stroke in the elderly, but only in those below 70 years. Atherosclerosis 2001; 159(1): 201–8PubMed Simons LA, Simons J, Friedlander Y, et al. Cholesterol and other lipids predict coronary heart disease and ischaemic stroke in the elderly, but only in those below 70 years. Atherosclerosis 2001; 159(1): 201–8PubMed
50.
Zurück zum Zitat Zuliani G, Cherubini A, Atti AR, et al. Low cholesterol levels are associated with short-term mortality in older patients with ischemic stroke. J Gerontol A Biol Sci Med Sci 2004; 59(3): 293–7PubMed Zuliani G, Cherubini A, Atti AR, et al. Low cholesterol levels are associated with short-term mortality in older patients with ischemic stroke. J Gerontol A Biol Sci Med Sci 2004; 59(3): 293–7PubMed
51.
Zurück zum Zitat Grundy SM, Cleeman JI, Rifkind BM, et al. Cholesterol lowering in the elderly population. Coordinating Committee of the National Cholesterol Education Program. Arch Intern Med 1999; 159(15): 1670–8PubMed Grundy SM, Cleeman JI, Rifkind BM, et al. Cholesterol lowering in the elderly population. Coordinating Committee of the National Cholesterol Education Program. Arch Intern Med 1999; 159(15): 1670–8PubMed
52.
Zurück zum Zitat Corti MC, Guralnik JM, Salive ME, et al. Clarifying the direct relation between total cholesterol levels and death from coronary heart disease in older persons. Ann Intern Med 1997; 126(10): 753–60PubMed Corti MC, Guralnik JM, Salive ME, et al. Clarifying the direct relation between total cholesterol levels and death from coronary heart disease in older persons. Ann Intern Med 1997; 126(10): 753–60PubMed
53.
Zurück zum Zitat Wood D, De Backer G, Faergeman O, et al. Prevention of coronary heart disease in clinical practice. Summary of recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. J Hypertens 1998; 16(10): 1407–14PubMed Wood D, De Backer G, Faergeman O, et al. Prevention of coronary heart disease in clinical practice. Summary of recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. J Hypertens 1998; 16(10): 1407–14PubMed
54.
Zurück zum Zitat Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285(19): 2486–97 Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285(19): 2486–97
55.
Zurück zum Zitat Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994 19; 344(8934): 1383–9 Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994 19; 344(8934): 1383–9
56.
Zurück zum Zitat Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333(20): 1301–7PubMed Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333(20): 1301–7PubMed
57.
Zurück zum Zitat The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339(19): 1349–57 The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339(19): 1349–57
58.
Zurück zum Zitat Miettinen TA, Pyörälä K, Olsson AG, et al. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S). Circulation 1997; 96(12): 4211–18PubMed Miettinen TA, Pyörälä K, Olsson AG, et al. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S). Circulation 1997; 96(12): 4211–18PubMed
59.
Zurück zum Zitat Lewis SJ, Moye LA, Sacks FM, et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. Ann Intern Med 1998; 129(9): 681–9PubMed Lewis SJ, Moye LA, Sacks FM, et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. Ann Intern Med 1998; 129(9): 681–9PubMed
60.
Zurück zum Zitat Hunt D, Young P, Simes J, et al. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: Results from the LIPID trial. Ann Intern Med 2001; 134(10): 931–40PubMed Hunt D, Young P, Simes J, et al. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: Results from the LIPID trial. Ann Intern Med 2001; 134(10): 931–40PubMed
61.
Zurück zum Zitat Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360: 1623–30PubMed Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360: 1623–30PubMed
62.
Zurück zum Zitat EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EURO-ASPIRE II Euro Heart Survey Programme. Eur Heart J 2001; 22(7): 554–72 EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EURO-ASPIRE II Euro Heart Survey Programme. Eur Heart J 2001; 22(7): 554–72
63.
Zurück zum Zitat Reid FD, Cook DG, Whincup PH. Use of statins in the secondary prevention of coronary heart disease: is treatment equitable? Heart 2002 Jul; 88(1): 15–19PubMed Reid FD, Cook DG, Whincup PH. Use of statins in the secondary prevention of coronary heart disease: is treatment equitable? Heart 2002 Jul; 88(1): 15–19PubMed
64.
Zurück zum Zitat Majeed A, Moser K, Maxwell R. Age, sex and practice variations in the use of statins in general practice in England and Wales. J Public Health Med 2000; 22(3): 275–9PubMed Majeed A, Moser K, Maxwell R. Age, sex and practice variations in the use of statins in general practice in England and Wales. J Public Health Med 2000; 22(3): 275–9PubMed
65.
Zurück zum Zitat Whincup PH, Emberson JR, Lennon L, et al. Low prevalence of lipid lowering drug use in older men with established coronary heart disease. Heart 2002; 88(1): 25–9PubMed Whincup PH, Emberson JR, Lennon L, et al. Low prevalence of lipid lowering drug use in older men with established coronary heart disease. Heart 2002; 88(1): 25–9PubMed
66.
Zurück zum Zitat Williams D, Bennett K, Feely J. Evidence for an age and gender bias in the secondary prevention of ischaemic heart disease in primary care. Br J Clin Pharmacol 2003; 55(6): 604–8PubMed Williams D, Bennett K, Feely J. Evidence for an age and gender bias in the secondary prevention of ischaemic heart disease in primary care. Br J Clin Pharmacol 2003; 55(6): 604–8PubMed
67.
Zurück zum Zitat Massing MW, Sueta CA, Chowdhury M, et al. Management among coronary artery disease patients with diabetes mellitus or advanced age. Am J Cardiol 2001; 87(5): 646–69, A10PubMed Massing MW, Sueta CA, Chowdhury M, et al. Management among coronary artery disease patients with diabetes mellitus or advanced age. Am J Cardiol 2001; 87(5): 646–69, A10PubMed
68.
Zurück zum Zitat De Wilde S, Cook DG, Carey IM, et al. Underuse of statins among older people. Lancet 2003; 362(9385): 746–7PubMed De Wilde S, Cook DG, Carey IM, et al. Underuse of statins among older people. Lancet 2003; 362(9385): 746–7PubMed
69.
Zurück zum Zitat Cutler JA, Sorlie PD, Wolz M, et al. Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988–1994 and 1999–2004. Hypertension 2008 Nov; 52(5): 818–27PubMed Cutler JA, Sorlie PD, Wolz M, et al. Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988–1994 and 1999–2004. Hypertension 2008 Nov; 52(5): 818–27PubMed
70.
Zurück zum Zitat Chobanian AV, Bakris GL, Black HR, et al., National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003 May 21; 289(19): 2560–72PubMed Chobanian AV, Bakris GL, Black HR, et al., National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003 May 21; 289(19): 2560–72PubMed
71.
Zurück zum Zitat Vasan RS, Beiser A, Seshadri S, et al. Residual lifetime risk for developing hypertension in middle-aged women and men: the Framingham Heart Study. JAMA 2002; 287(8): 1003–10PubMed Vasan RS, Beiser A, Seshadri S, et al. Residual lifetime risk for developing hypertension in middle-aged women and men: the Framingham Heart Study. JAMA 2002; 287(8): 1003–10PubMed
72.
Zurück zum Zitat Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988–1991. Hypertension 1995; 25(3): 305–13PubMed Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988–1991. Hypertension 1995; 25(3): 305–13PubMed
73.
Zurück zum Zitat Franklin SS, Gustin 4th W, Wong ND, et al. Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circulation 1997; 96(1): 308–15PubMed Franklin SS, Gustin 4th W, Wong ND, et al. Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circulation 1997; 96(1): 308–15PubMed
74.
Zurück zum Zitat Lawes CM, Bennett DA, Feigin VL, et al. Blood pressure and stroke: an overview of published reviews. Stroke 2004; 35(4): 1024PubMed Lawes CM, Bennett DA, Feigin VL, et al. Blood pressure and stroke: an overview of published reviews. Stroke 2004; 35(4): 1024PubMed
75.
Zurück zum Zitat Neal B, MacMahon S, Chapman N, Blood Pressure Lowering Treatment Trialists’Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists’ Collaboration. Lancet 2000; 356(9246): 1955–64PubMed Neal B, MacMahon S, Chapman N, Blood Pressure Lowering Treatment Trialists’Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists’ Collaboration. Lancet 2000; 356(9246): 1955–64PubMed
76.
Zurück zum Zitat Mancia G, De Backer G, Dominiczak A, et al. ESH-ESC Task Force on the Management of Arterial Hypertension. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 2007 Sep; 25(9): 1751–62. Erratum in: J Hypertens. 2007; 25 (10): 2184PubMed Mancia G, De Backer G, Dominiczak A, et al. ESH-ESC Task Force on the Management of Arterial Hypertension. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 2007 Sep; 25(9): 1751–62. Erratum in: J Hypertens. 2007; 25 (10): 2184PubMed
77.
Zurück zum Zitat Oates DJ, Berlowitz DR, Glickman ME, et al. Blood pressure and survival in the oldest old. J Am Geriatr Soc 2007 Mar; 55(3): 383–8PubMed Oates DJ, Berlowitz DR, Glickman ME, et al. Blood pressure and survival in the oldest old. J Am Geriatr Soc 2007 Mar; 55(3): 383–8PubMed
78.
Zurück zum Zitat Gueyffier F. Antihypertensive treatment. Lancet 1999 Sep 18; 354(9183): 1028; author reply 1028–9PubMed Gueyffier F. Antihypertensive treatment. Lancet 1999 Sep 18; 354(9183): 1028; author reply 1028–9PubMed
79.
Zurück zum Zitat Bulpitt CJ, Beckett NS, Cooke J, et al., Hypertension in the Very Elderly Trial Working Group. Results of the pilot study for the Hypertension in the Very Elderly Trial. J Hypertens 2003; 21(12): 2409–17PubMed Bulpitt CJ, Beckett NS, Cooke J, et al., Hypertension in the Very Elderly Trial Working Group. Results of the pilot study for the Hypertension in the Very Elderly Trial. J Hypertens 2003; 21(12): 2409–17PubMed
80.
Zurück zum Zitat SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265(24): 3255–64 SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265(24): 3255–64
81.
Zurück zum Zitat Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997; 350(9080): 757–64PubMed Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997; 350(9080): 757–64PubMed
82.
Zurück zum Zitat Beckett NS, Peters R, Fletcher AE, et al., HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358(18): 1887–98PubMed Beckett NS, Peters R, Fletcher AE, et al., HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358(18): 1887–98PubMed
83.
Zurück zum Zitat Meissner I, Whisnant JP, Sheps SG, et al. Detection and control of high blood pressure in the community: do we need a wake-up call? Hypertension 1999; 34(3): 466–71PubMed Meissner I, Whisnant JP, Sheps SG, et al. Detection and control of high blood pressure in the community: do we need a wake-up call? Hypertension 1999; 34(3): 466–71PubMed
84.
Zurück zum Zitat Lloyd-Jones DM, Evans JC, Larson MG, et al. Differential control of systolic and diastolic blood pressure: factors associated with lack of blood pressure control in the community. Hypertension 2000; 36(4): 594–9PubMed Lloyd-Jones DM, Evans JC, Larson MG, et al. Differential control of systolic and diastolic blood pressure: factors associated with lack of blood pressure control in the community. Hypertension 2000; 36(4): 594–9PubMed
85.
Zurück zum Zitat Ambrosioni E, Leonetti G, Pessina AC, et al. Patterns of hypertension management in Italy: results of a pharmacoepidemiological survey on antihypertensive therapy. Scientific Committee of the Italian Pharmacoepidemiological Survey on Antihypertensive Therapy. J Hypertens 2000; 18(11): 1691–9PubMed Ambrosioni E, Leonetti G, Pessina AC, et al. Patterns of hypertension management in Italy: results of a pharmacoepidemiological survey on antihypertensive therapy. Scientific Committee of the Italian Pharmacoepidemiological Survey on Antihypertensive Therapy. J Hypertens 2000; 18(11): 1691–9PubMed
86.
Zurück zum Zitat Burt VL, Cutler JA, Higgins M, et al. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the health examination surveys, 1960 to 1991. Hypertension 1995; 26(1): 60–9. Erratum in: Hypertension 1996; 27 (5): 1192PubMed Burt VL, Cutler JA, Higgins M, et al. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the health examination surveys, 1960 to 1991. Hypertension 1995; 26(1): 60–9. Erratum in: Hypertension 1996; 27 (5): 1192PubMed
87.
Zurück zum Zitat Hyman DJ, Pavlik VN. Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med 2001; 345(7): 479–86. Erratum in: N Engl J Med 2002; 346 (7): 544PubMed Hyman DJ, Pavlik VN. Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med 2001; 345(7): 479–86. Erratum in: N Engl J Med 2002; 346 (7): 544PubMed
88.
Zurück zum Zitat Ostchega Y, Dillon CF, Hughes JP, et al. Trends in hypertension prevalence, awareness, treatment, and control in older U.S. adults: data from the National Health and Nutrition Examination Survey 1988 to 2004. J Am Geriatr Soc 2007; 55(7): 1056–65PubMed Ostchega Y, Dillon CF, Hughes JP, et al. Trends in hypertension prevalence, awareness, treatment, and control in older U.S. adults: data from the National Health and Nutrition Examination Survey 1988 to 2004. J Am Geriatr Soc 2007; 55(7): 1056–65PubMed
89.
Zurück zum Zitat Stratton MA, Salinas RC. Medication management in the elderly. J Okla State Med Assoc 2003; 96(3): 116–22PubMed Stratton MA, Salinas RC. Medication management in the elderly. J Okla State Med Assoc 2003; 96(3): 116–22PubMed
90.
Zurück zum Zitat Anderson G, Kerluke K. Distribution of prescription drug exposures in the elderly: description and implications. J Clin Epidemiol 1996; 49(8): 929–35PubMed Anderson G, Kerluke K. Distribution of prescription drug exposures in the elderly: description and implications. J Clin Epidemiol 1996; 49(8): 929–35PubMed
91.
Zurück zum Zitat Jörgensen T, Johansson S, Kennerfalk A, et al. Prescription drug use, diagnoses, and healthcare utilization among the elderly. Ann Pharmacother 2001; 35(9): 1004–9PubMed Jörgensen T, Johansson S, Kennerfalk A, et al. Prescription drug use, diagnoses, and healthcare utilization among the elderly. Ann Pharmacother 2001; 35(9): 1004–9PubMed
92.
Zurück zum Zitat Kennerfalk A, Ruigómez A, Wallander MA, et al. Geriatric drug therapy and healthcare utilization in the United Kingdom. Ann Pharmacother 2002; 36(5): 797–803PubMed Kennerfalk A, Ruigómez A, Wallander MA, et al. Geriatric drug therapy and healthcare utilization in the United Kingdom. Ann Pharmacother 2002; 36(5): 797–803PubMed
93.
Zurück zum Zitat Rathore SS, Mehta RH, Wang Y, et al. Effects of age on the quality of care provided to older patients with acute myocardial infarction. Am J Med 2003; 114(4): 307–15PubMed Rathore SS, Mehta RH, Wang Y, et al. Effects of age on the quality of care provided to older patients with acute myocardial infarction. Am J Med 2003; 114(4): 307–15PubMed
94.
Zurück zum Zitat Redelmeier DA, Tan SH, Booth GL. The treatment of unrelated disorders in patients with chronic medical diseases. N Engl J Med 1998; 338(21): 1516–20PubMed Redelmeier DA, Tan SH, Booth GL. The treatment of unrelated disorders in patients with chronic medical diseases. N Engl J Med 1998; 338(21): 1516–20PubMed
95.
Zurück zum Zitat Schmader KE, Hanlon JT, Fillenbaum GG, et al. Medication use patterns among demented, cognitively impaired and cognitively intact community-dwelling elderly people. Age Ageing 1998; 27(4): 493–501PubMed Schmader KE, Hanlon JT, Fillenbaum GG, et al. Medication use patterns among demented, cognitively impaired and cognitively intact community-dwelling elderly people. Age Ageing 1998; 27(4): 493–501PubMed
96.
Zurück zum Zitat Le Couteur DG, Hilmer SN, Glasgow N, et al. Prescribing in older people. Aust Fam Physician 2004; 33(10): 777–81PubMed Le Couteur DG, Hilmer SN, Glasgow N, et al. Prescribing in older people. Aust Fam Physician 2004; 33(10): 777–81PubMed
97.
Zurück zum Zitat Fogari R, Zoppi A. Effect of antihypertensive agents on quality of life in the elderly. Drugs Aging 2004; 21(6): 377–93PubMed Fogari R, Zoppi A. Effect of antihypertensive agents on quality of life in the elderly. Drugs Aging 2004; 21(6): 377–93PubMed
98.
Zurück zum Zitat Aronow WS. Treating hypertension in older adults: safety considerations. Drug Saf 2009; 32(2): 111–18PubMed Aronow WS. Treating hypertension in older adults: safety considerations. Drug Saf 2009; 32(2): 111–18PubMed
99.
Zurück zum Zitat Onder G, Pedone C, Landi F, et al. Adverse drug reactions as cause of hospital admissions: results from the Italian Group of Pharmacoepidemiology in the Elderly (GIFA). J Am Geriatr Soc 2002; 50(12): 1962–8PubMed Onder G, Pedone C, Landi F, et al. Adverse drug reactions as cause of hospital admissions: results from the Italian Group of Pharmacoepidemiology in the Elderly (GIFA). J Am Geriatr Soc 2002; 50(12): 1962–8PubMed
100.
Zurück zum Zitat Bates DW. Drugs and adverse drug reactions: how worried should we be? JAMA 1998; 279(15): 1216–17PubMed Bates DW. Drugs and adverse drug reactions: how worried should we be? JAMA 1998; 279(15): 1216–17PubMed
101.
Zurück zum Zitat Tinetti ME, Bogardus Jr ST, Agostini JV. Potential pitfalls of disease-specific guidelines for patients with multiple conditions. N Engl J Med 2004 30; 351(27): 2870–4PubMed Tinetti ME, Bogardus Jr ST, Agostini JV. Potential pitfalls of disease-specific guidelines for patients with multiple conditions. N Engl J Med 2004 30; 351(27): 2870–4PubMed
102.
Zurück zum Zitat Frazier SC. Health outcomes and polypharmacy in elderly individuals: an integrated literature review. J Gerontol Nurs 2005 Sep; 31(9): 4–11PubMed Frazier SC. Health outcomes and polypharmacy in elderly individuals: an integrated literature review. J Gerontol Nurs 2005 Sep; 31(9): 4–11PubMed
103.
Zurück zum Zitat Landi F, Russo A, Liperoti R, et al. Impact of inappropriate drug use on physical performance among a frail elderly population living in the community. Eur J Clin Pharmacol 2007; 63(8): 791–9PubMed Landi F, Russo A, Liperoti R, et al. Impact of inappropriate drug use on physical performance among a frail elderly population living in the community. Eur J Clin Pharmacol 2007; 63(8): 791–9PubMed
Metadaten
Titel
Variability in the Prescription of Cardiovascular Medications in Older Patients
Correlates and Potential Explanations
verfasst von
Dr Cinzia Maraldi
Fabrizia Lattanzio
Graziano Onder
Massimo Gallerani
Silvia Bustacchini
Giuseppe De Tommaso
Stefano Volpato
Publikationsdatum
01.12.2009
Verlag
Springer International Publishing
Erschienen in
Drugs & Aging / Ausgabe Sonderheft 1/2009
Print ISSN: 1170-229X
Elektronische ISSN: 1179-1969
DOI
https://doi.org/10.2165/11534650-000000000-00000

Weitere Artikel der Sonderheft 1/2009

Drugs & Aging 1/2009 Zur Ausgabe

Conclusions

Conclusions

EditorialNotes

Foreword

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.